Journal
MABS
Volume 2, Issue 2, Pages 137-147Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.2.2.11271
Keywords
certolizumab pegol; rheumatoid arthritis; Crohn disease; TNF alpha; PEGylated; methotrexate
Categories
Ask authors/readers for more resources
Certolizumab pegol (Cimzia*) is currently the only PEGylated anti-TNF alpha biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available